[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 408
Citations 0
Lab Reports
July 3, 2013

New Clues, Potential Solution to Cancer Drug’s Cardiotoxicity

Author Affiliations

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2013;310(1):22. doi:10.1001/jama.2013.7639

The anticancer drug sunitinib, which is known to damage heart muscle, destroys cells called pericytes that wrap around blood vessels and are essential to their function, report scientists from Amgen, in South San Francisco, California, in collaboration with investigators at the University of Texas and Baylor College of Medicine, in Houston (Chintalgattu V et al. Sci Transl Med. 2013;5[187]:187ra69).

Pericytes are dependent on signaling by platelet-derived growth factor receptor (PDGFR), a protein targeted by sunitinib. By using the PDGFR inhibitor CP-673451, the researchers were able to recapitulate the kind of cardiotoxicity that sunitinib produces.